{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-067013","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.200065+00:00","generated_at":"2026-05-22T04:40:43.190014+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"4DMT Q1 net loss $48M; initiates 4D-150 Phase 3 in wet AMD; cash runway to 2028","bullets":["Net loss $48.0M vs $32.4M YoY; R&D expenses $40.7M (+46% YoY) due to Phase 3 startup.","Cash $458M (down from $505M Dec 2024); expected to fund operations into 2028.","First patients enrolled in 4D-150 Phase 3 (4FRONT-1) in wet AMD; 4FRONT-2 starts Q3 2025; topline H2 2027.","FDA RMAT designation for 4D-150 in DME; FDA aligned on single Phase 3 trial for BLA.","Pipeline focused on 4D-150 and 4D-710; paused/terminated 4D-175, 4D-725, 4D-310, 4D-110, 4D-125."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-067013","json":"https://secwatch.observer/filing/0000950170-25-067013.json","markdown":"https://secwatch.observer/filing/0000950170-25-067013.md","text":"https://secwatch.observer/filing/0000950170-25-067013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/0000950170-25-067013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:40:43.190014+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}